Global Coronavirus Partnering 2014 to 2021 provides the full collection of Coronavirus disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014.
Trends in Coronavirus partnering deals Financial deal terms for headline, upfront and royalty by stage of development Coronavirus partnering agreement structure Coronavirus partnering contract documents Top Coronavirus deals by value Most active Coronavirus dealmakers
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Coronavirus disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Coronavirus deals.
The report presents financial deal terms values for Coronavirus deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
The initial chapters of this report provide an orientation of Coronavirus dealmaking trends.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in Coronavirus dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.
Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.
Chapter 4 provides a review of the leading Coronavirus deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Coronavirus dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 5 provides comprehensive access to Coronavirus deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of all Coronavirus partnering deals by specific Coronavirus target announced since 2014. The chapter is organized by specific Coronavirus therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all Coronavirus partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Coronavirus partnering and dealmaking since 2014.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Coronavirus technologies and products.
Report scope Global Coronavirus Partnering 2014 to 2021 is intended to provide the reader with an in-depth understanding and access to Coronavirus trends and structure of deals entered into by leading companies worldwide.
Global Coronavirus Partnering 2014 to 2021 includes: Trends in Coronavirus dealmaking in the biopharma industry since 2014 Access to headline, upfront, milestone and royalty data Access to numerous Coronavirus deal contract documents Comprehensive access to over 1000 Coronavirus deal records The leading Coronavirus deals by value since 2014 Most active Coronavirus dealmakers since 2014
In Global Coronavirus Partnering 2014 to 2021, available deals and contracts are listed by: Headline value Upfront payment value Royalty rate value Stage of development at signing Deal component type Technology type Specific therapy indication
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Coronavirus Partnering 2014-2021 report provides comprehensive access to available deals and contract documents for over 1000 Coronavirus deals. Analyzing actual contract agreements allows assessment of the following: • What are the precise rights granted or optioned? • What is actually granted by the agreement to the partner company? • What exclusivity is granted? • What is the payment structure for the deal? • How are the sales and payments audited? • What is the deal term? • How are the key terms of the agreement defined? • How are IPRs handled and owned? • Who is responsible for commercialization? • Who is responsible for development, supply, and manufacture? • How is confidentiality and publication managed? • How are disputes to be resolved? • Under what conditions can the deal be terminated? • What happens when there is a change of ownership? • What sublicensing and subcontracting provisions have been agreed? • Which boilerplate clauses does the company insist upon? • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? • Which jurisdiction does the company insist upon for agreement law?
Our reports have been used by over 10K customers, including:
Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective This report provides you with a landscape description and analysis of prodrug antibodies and cytokines employing conventional and novel masking technology...
The Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021 report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading biopharma companies. This report provides...
The Global Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021 report provides details of the latest distribution agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully revised and updated, the report provides details of distribution agreements from...
The Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2014-2021 report provides a detailed understanding and analysis of how and why companies enter business, product, technology and royalty assets. The report provides a detailed understanding and analysis of how and why companies enter business, product,...
The aptamers market valued at an estimated USD 151 million in 2021 and is projected to reach USD 342 million by 2026, at a CAGR of 17.7% during the forecast period. Growth of aptamers market is attributed to factors such as increase in number of clinical trials for development of aptamer-based therapeutics, increase in awareness about advantages...
The global flow cytometry market size is projected to reach USD 6.3 billion by 2026 from USD 4.3 billion in 2021, growing at a CAGR of 8.1% from 2020 to 2026. The key factors driving the growth of this market include technological advancements in flow cytometers, the increasing adoption of flow cytometry in research and clinical trials, growing...
The global prepacked chromatography columns market reached a value of US$ 2.24 Billion in 2020. Looking forward, the analyst expects the market to grow at a CAGR of 3.5% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on...
The global western blotting market is projected to reach USD 1.4 billion by 2026 from USD 1.0 billion in 2021, at a CAGR of 6.7% during the forecast period. Technological advancements, increasing government funding in the field of biomedical research, growing demand for personalized medicine, and the rising prevalence of HIV are the key factors...
120 pages •
By Infiniti Research Limited
• Aug 2021
Global Mycoplasma Testing Market 2021-2025 The analyst has been monitoring the mycoplasma testing market and it is poised to grow by $ 496.87 mn during 2021-2025, progressing at a CAGR of over 11% during the forecast period. Our report on the mycoplasma testing market provides a holistic analysis, market size and forecast,...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.